ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO804

Variability of Pre-Dialysis Serum Sodium, a Risk Factor of Survival in Hemodialysis Patients: Results from the Global MONDO Initiative

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Ye, Xiaoling, Renal Research Institute, New York, New York, United States
  • Kooman, Jeroen, Maastricht University Medical Centre, Maastricht, Netherlands
  • van der Sande, Frank, Maastricht University Medical Centre, Maastricht, Netherlands
  • Canaud, Bernard J., FMC Deutschland GmbH, Bad Homburg, Germany
  • Stuard, Stefano, Fresenius Medical Care, Bad Homburg, Germany
  • Etter, Michael, Fresenius Medical Care Asia Pacific, Wanchai, HONG KONG, China
  • Xu, Xiaoqi, Fresenius Medical Care Asia Pacific, Wanchai, HONG KONG, China
  • Guinsburg, Adrian M., Fresenius Medical Care, Bad Homburg, Germany
  • Usvyat, Len A., Fresenius Medical Care North America, Melrose, Massachusetts, United States
  • Wang, Yuedong, University of California - Santa Barbara, Santa Barbara, California, United States
  • Power, Albert J., Richard Bright Renal Unit, Bristol, United Kingdom
  • Kotanko, Peter, Renal Research Institute, New York, New York, United States
  • Raimann, Jochen G., Renal Research Institute, New York, New York, United States

Group or Team Name

  • The MONDO Initiative
Background

Variability of laboratory parameters and serum sodium (SNa) observed to associated with adverse physical conditions in chronic hemodialysis (HD) patients (pts) [Nakazato Y et al]. SNa, the main determinant of plasma osmolality, play a key role in fluid shifts between the extra-& intracellular compartments. Variability SNa, denoted as the measured-to-measured variation, affects the stability of cell volume.

Methods

All adult incident pts with more than 5 SNas during the first year on HD were included, outcomes were recorded over a 2 yrs period. Average baseline SNa as well as variabilities were computed by standard deviation (SD) of the residual, SD, relative range (the difference between the largest and smallest), average real variability (ARV). Cox proportional models with bivariate spline functions were applied to study the joint effects of SD of residual, SD, ARV and relative range of SNa, respectively. Cox proportional models with multiple adjustments were also used to further evaluate the adverse effect of SNa variability.

Results

Out of 30,174 pts (EU:15,660, Asia:8,749,US:2,691,UK:2,282, South America:791) were included, 7,021 (23.3%) died. Hyponatremia (SNa<=135) was the most prominent predictor of increase mortality. For pts with SNa>135, we didn't observe an association between SD residual and mortality. Increased risk of death with higher SD and ARV appeared to be present at all levels of SNa. A more pronounced effect of relative range was observed compared to SD and ARV. More significant effect was observed with the maximal SNa happened before the minimal SNa [Figure 1]. Cox proportional model with adjustments also yield the same results.

Conclusion

Given the positive association between mortality and hiher SNa range,S, ARV regardless of the SNa level, these measures constitute novel prognostic indicators in HD therapy.